Epinephrine Autoinjector Market Report 2025 (Global Edition)

Global Epinephrine Autoinjector Market Report 2024 Market Size Split by Product (Single-Dose Autoinjectors, Multiple-Dose Autoinjectors), by Distribution (Retail Pharmacies, Hospital Pharmacies, Onlin...

Epinephrine Autoinjector Market Report Description

We have various report editions of Epinephrine Autoinjector Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Epinephrine Autoinjector Market Insights Video

Competitive Landscape of the Epinephrine Autoinjector Market

The analysis also included a thorough examination of the competition landscape in the worldwide epinephrine autoinjector market. The research covers competitive analysis such as market structure, key players' market share, player positioning, top winning strategies, competitive dashboard, and business assessment quadrants. Additionally, full biographies of all important companies have been supplied. Adamis Pharmaceuticals Corporation, Alk-Abello A/S, Amneal Pharmaceuticals, Antares Pharma, and Bausch & Lomb Inc. are among the firms covered.

August 2022, Amphastar Pharmaceuticals Inc. stated that the United States Food and Drug Administration has approved the company's New Drug Application for Epinephrine Single Dose Pre-Filled Syringe.

(Source: https://ir.amphastar.com/websites/amphastar/English/2110/news-detail.html?airportNewsID=15181bef-e8cc-43ac-b9f0-6c7c31ad8ea7)

February 2022, Sanofi bought Amunix, providing access to Amunix Pro-XTEN, XPAT, and XPAC technology for next-generation Conditionally Activated Biologics.

(Source: https://www.pbiforum.net/mag/featured/sanofi-completes-acquisition-of-amunix/)

Top Companies Market Share in Epinephrine Autoinjector Industry: (In no particular order of Rank)

• Adamis Pharmaceuticals Corporation
• Alk-Abello A/S
• Amneal Pharmaceuticals
• Antares Pharma
• Bausch & Lomb Inc.
• Kaleo Inc.
• Mylan NV
• Pfizer Inc
• Sandoz
• Sanofi SA
• Teva Pharmaceutical Industries Ltd
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Epinephrine Autoinjector Market

Which Region Dominates the Epinephrine Autoinjector Market in 2024?

According to Cognitive Market Research, North America has long dominated the global epinephrine autoinjector market. The presence of large firms such as Mylan, Pfizer, and several other pharmaceutical companies has cemented the region's status as an industry leader. Historically, North American countries accounted for 40% of worldwide autoinjector device sales. Furthermore, North America was the first to adopt novel technology and gadgets designed for emergency treatment of allergic reactions such as anaphylaxis. This has secured a steady supply and widespread acceptance of autoinjectors throughout the region.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Epinephrine Autoinjector market due to growing understanding of life-threatening food and medication allergies. As allergy rates rise, Asia Pacific has emerged as an appealing investment destination for device manufacturers. Favorable rules and rising healthcare costs have prompted both global and local enterprises to develop their operations in the region. For example, numerous North American enterprises have formed partnerships with local pharmaceutical firms to facilitate market entry and distribution. This enables them to appeal to a large population base while maintaining relatively low manufacturing costs.

The current report Scope analyzes Epinephrine Autoinjector Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Epinephrine Autoinjector

According to Cognitive Market Research, the global Epinephrine Autoinjector market size was estimated at USD 2,158.2 Million out of which North America held the major market of more than 40% of the global revenue with a market size of USD 863.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.2% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Epinephrine Autoinjector market with a market size of USD 681.13 million in 2024 and is projected to grow at a CAGR of 6.0% during the forecast period. The region's growth is also driven by an increase in demand for technologically advanced products.
• The Canada Epinephrine Autoinjector market had a market share of USD 103.59 million in 2024 and is projected to grow at a CAGR of 7.0% during the forecast period. The region is anticipated to be driven by the expanding treatment-seeking population due to increased awareness of anaphylaxis.
• The Mexico Epinephrine Autoinjector market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD 78.56 million in 2024.

Europe Epinephrine Autoinjector

According to Cognitive Market Research, the global Epinephrine Autoinjector market size was estimated at USD 2,158.2 Million out of which Europe held the market of more than 30% of the global revenue with a market size of USD 647.46 million in 2024 and will grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2031.

• The United Kingdom Epinephrine Autoinjector market had a market share of USD 108.77 million in 2024 and is projected to grow at a CAGR of 7.3% during the forecast period. This expansion is due to factors such as increased manufacture of generic epinephrine in the region
• The France Epinephrine Autoinjector market is projected to witness growth at a CAGR of 5.7% during the forecast period with a market size of USD 59.57 million in 2024.
• According to Cognitive Market Research, the Germany Epinephrine Autoinjector market size was valued at USD 128.20 million in 2024 and is projected to grow at a CAGR of 6.7% during the forecast period. In Germany, Epinephrine Autoinjector sales surge due to the increasing number of persons with life-threatening food allergies, as well as the rise in chronic diseases linked to allergies.
• The Italy Epinephrine Autoinjector market is projected to witness growth at a CAGR of 5.9% during the forecast period with a market size of USD 55.68 million in 2024.
• The Russia Epinephrine Autoinjector market is projected to witness growth at a CAGR of 5.5% during the forecast period with a market size of USD 100.36 million in 2024.
• The Spain Epinephrine Autoinjector market is projected to witness growth at a CAGR of 5.6% during the forecast period with a market size of USD 53.09 million in 2024
• The Luxembourg Epinephrine Autoinjector market is projected to witness growth at a CAGR of 6.6% during the forecast period with a market size of USD 20.07 million in 2024.
• The Portugal Epinephrine Autoinjector market is projected to witness growth at a CAGR of 6.3% during the forecast period with a market size of USD 13.60 million in 2024.
• The Greece Epinephrine Autoinjector market is projected to witness growth at a CAGR of 6.8% during the forecast period with a market size of USD 7.77 million in 2024.
• Rest of Europe Epinephrine Autoinjector market is projected to witness growth at a CAGR of 5.2% during the forecast period with a market size of USD 100.36 million in 2024.

Asia Pacific Epinephrine Autoinjector

According to Cognitive Market Research, the global Epinephrine Autoinjector market size was estimated at USD 2,158.2 Million out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 496.39 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031.

• According to Cognitive Market Research, the China Epinephrine Autoinjector market size was valued at USD 223.37 million in 2024 and is projected to grow at a CAGR of 9.5% during the forecast period. Epinephrine Autoinjector sales surge in China due to economic diversity, urbanization, and a young population are all driving up demand for Epinephrine Autoinjector products and services in the region.
• The Japan Epinephrine Autoinjector market is projected to witness growth at a CAGR of 8.5% during the forecast period with a market size of USD 68.50 million in 2024.
• The India Epinephrine Autoinjector market had a market share of USD 59.57 million in 2024 and is projected to grow at a CAGR of 11.8% during the forecast period. The aging population in the region, as well as the government's increased commitment to providing affordable healthcare, are factors driving up demand for Epinephrine Autoinjector Market.
• The South Korea Epinephrine Autoinjector market is projected to witness growth at a CAGR of 9.1% during the forecast period with a market size of USD 49.64 million in 2024.
• The Australia Epinephrine Autoinjector market is projected to witness growth at a CAGR of 9.7% during the forecast period with a market size of USD 25.81 million in 2024.
• The South East Asia Epinephrine Autoinjector market is projected to witness growth at a CAGR of 11.0% during the forecast period with a market size of USD 34.25 million in 2024.
• The Rest of Asia Pacific Epinephrine Autoinjector market is projected to witness growth at a CAGR of 9.8% during the forecast period with a market size of USD 35.24 million in 2024.

South America Epinephrine Autoinjector

According to Cognitive Market Research, the global Epinephrine Autoinjector market size was estimated at USD 2,158.2 Million out of which Latin America market of more than 5% of the global revenue with a market size of USD 107.91 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.4% from 2024 to 2031.

• According to Cognitive Market Research, the Brazil Epinephrine Autoinjector market size was valued at USD 46.19 million in 2024 and is projected to grow at a CAGR of 8.0% during the forecast period. The region benefits from a huge population, rising disposable income, and increased urbanization, which drives up demand for Epinephrine Autoinjector products and services.
• Argentina Epinephrine Autoinjector market had a market share of USD 18.13 million in 2024 and is projected to grow at a CAGR of 8.3% during the forecast period. Economic fluctuations and political instability in certain nations can have an impact on market dynamics and consumer behavior.
• Colombia Epinephrine Autoinjector market is projected to witness growth at a CAGR of 7.2% during the forecast period with a market size of USD 9.60 million in 2024.
• Peru Epinephrine Autoinjector market is projected to witness growth at a CAGR of 7.6% during the forecast period with a market size of USD 8.85 million in 2024.
• Chile Epinephrine Autoinjector market is projected to witness growth at a CAGR of 7.7% during the forecast period with a market size of USD 7.77 million in 2024.
• The Rest of Latin America Epinephrine Autoinjector market is projected to witness growth at a CAGR of 6.5% during the forecast period with a market size of USD 17.37 million in 2024.

Middle East and Africa Epinephrine Autoinjector

According to Cognitive Market Research, the global Epinephrine Autoinjector market size was estimated at USD 2,158.2 Million out of which Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 43.16 million in 2024 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2024 to 2031.

• The GCC Countries Epinephrine Autoinjector market is projected to witness growth at a CAGR of 8.5% during the forecast period with a market size of USD 18.47 million in 2024. Epinephrine Autoinjector sales flourish due to advancements in healthcare and the availability of more accessible products have all contributed to market expansion.
• The Egypt Epinephrine Autoinjector market is projected to witness growth at a CAGR of 8.1% during the forecast period with a market size of USD 4.53 million in 2024.
• The South Africa Epinephrine Autoinjector market is projected to witness growth at a CAGR of 8.7% during the forecast period with a market size of USD 6.82 million in 2024. Epinephrine Autoinjector sales flourish in the South Africa due to growing knowledge and need for emergency allergy treatment.
• The Turkey Epinephrine Autoinjector market is projected to witness growth at a CAGR of 7.2% during the forecast period with a market size of USD 3.71 million in 2024.
• The Nigeria Epinephrine Autoinjector market is projected to witness growth at a CAGR of 6.8% during the forecast period with a market size of USD 4.53 million in 2024.
• The Rest of MEA Epinephrine Autoinjector market is projected to witness growth at a CAGR of 6.7% during the forecast period with a market size of USD 5.09 million in 2024.

Epinephrine Autoinjector Market Analysis

Epinephrine Autoinjector Market Product Type Segment Analysis

According to Cognitive Market Research, Multiple-Dose Autoinjectors dominate the market. The increasing incidence of anaphylaxis in adults and the elderly is the key driver of the Multiple-Dose segment's rise. Epinephrine is recommended as the first-line treatment for anaphylaxis. The increasing recommendation of single-dose medications for adult patients is driving the segment's rise. Furthermore, market companies are focusing on offering generic, low-cost items. This is driving up the demand for low-cost therapy solutions for anaphylactic reactions.

The market's fastest growing segment is single-dose autoinjectors. The rising occurrence of anaphylaxis in children is the primary driver of growth in the Single-Dose sector. Furthermore, increased commercialization of epinephrine auto-injectors for infants in the United States, as well as FDA approval of generic versions, are boosting the growth of the low dose segment market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Epinephrine Autoinjector Industry. Request a Free Sample PDF!

Epinephrine Autoinjector Market Distribution Channel Category Segment Analysis

According to Cognitive Market Research, Retail pharmacies dominated the distribution channel segment. Retail pharmacies are predicted to have a significant revenue share over the projection period. Sudden reactions such as anaphylactic shocks and cardiac arrest are more common outside the hospital. And such responses must be treated as soon as they occur. In emergency cases, patients are expected to obtain epinephrine from retail pharmacies. This further dominates the retail pharmacies segment and propels the worldwide epinephrine autoinjector market. Furthermore, rising demand for epinephrine pens and automated external defibrillators is expected to fuel the segment's expansion.

The online retailers segment is predicted to grow the fastest during the projection period. With the increasing ubiquity of the internet and the availability of smartphones, e-commerce has had amazing development across a wide range of categories, from garments to medications, and consumers have begun purchasing the majority of their needs through online platforms.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Epinephrine Autoinjector End-user Segment Analysis

According to Cognitive Market Research, the hospitals and clinics sector accounts for the biggest market share. Epinephrine auto-injectors are used by healthcare professionals in hospitals and clinics to treat anaphylaxis in an emergency. The market is expanding at a rapid pace. It is owing to the widespread use of autoinjector devices by emergency departments in hospitals and clinics. The availability of professional HCPs with knowledge and skills draws many patients to hospitals and clinics.

The Homecare Settings sector is rapidly expanding in the Epinephrine Autoinjector Market for a variety of reasons. One of the primary elements driving this growth is an increasing demand for obtaining healthcare services at home. Many people find it easier and more comfortable to manage their health concerns in familiar surroundings.

• Hospitals & Clinics
• Homecare Settings
• Schools & Educational Institutions

Epinephrine Autoinjector Age-group Segment Analysis

According to Cognitive Market Research, the age group 6-12 years is projected to hold a substantial market share with the highest CAGR during the forecast period. Children aged 6-12 are at a higher risk of anaphylaxis and currently hold the top spot in the market, with a projected significant growth in the future. Nevertheless, there is a rise in the occurrence of anaphylaxis among older individuals and it is projected to continue increasing rapidly. The prevalence of anaphylaxis in children is increasing, necessitating prompt and efficient treatment. The government and regulatory agencies are implementing measures to protect children aged 6 to 12 from potentially deadly reactions. Epinephrine administered via auto-injectors works quickly and effectively in addressing severe symptoms in children. Therefore, it is always advised to have epinephrine auto-injectors readily available for children in schools to prevent life-threatening situations.

The Epinephrine Autoinjector Market is fastest growing among children under 6 years age Group. The prevalence of allergies in young children has been increasing. Allergies to common triggers including food, insect stings, and drugs can be severe and sometimes fatal. Epinephrine autoinjectors are the first-line treatment for anaphylaxis, a severe allergic reaction, and are critical in handling such emergencies.

• Assembly
• Distribution
• Kitting
• Order Picking
• Storage
• Others

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion